⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627410 | 1.00 | — | — | |
| SCHEMBL25464732 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL21598909 | 0.97 | AOC1 (0.30) | — | |
| SCHEMBL16105683 | 0.81 | AOC1 (0.31) | — | |
| SCHEMBL13446015 | 0.80 | — | — | |
| SCHEMBL15251642 | 0.80 | — | — | |
| SCHEMBL15604717 | 0.80 | — | — | |
| SCHEMBL24857315 | 0.78 | — | — | |
| SCHEMBL5404483 | 0.75 | — | — | |
| SCHEMBL18234096 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220433-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220435-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023212231-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212237-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212239-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-3272749-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2880032-B1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015116060-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| US-8901305-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901305-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140038999-A1 | Aryl Lactam Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-06 | — | — | US | disclosed |
| WO-2014022167-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |